The targeted delivery of nucleic acid therapeutics has been revolutionized by the development of GalNAc conjugation. By exploiting the high-affinity interaction between GalNAc and the asialoglycoprotein receptor (ASGPR) expressed predominantly on hepatocytes, researchers can achieve tissue-specific delivery with unprecedented potency. CD BioGlyco provides a premier solution-phase-based GalNAc-RNA delivery service, designed to meet the rigorous demands of modern drug discovery and molecular biology. This service focuses on the precise post-synthetic conjugation of triantennary GalNAc clusters to various RNA modalities, including siRNA and antisense oligonucleotides (ASOs). By utilizing a solution-phase approach, we overcome the steric hindrances and coupling inefficiencies often encountered in solid-phase synthesis, ensuring that every molecule of your precious RNA is optimized for hepatic uptake and therapeutic effect.
We leverage state-of-the-art chemical methodologies to ensure the integrity and functionality of GalNAc-RNA conjugates. Our core technological pillars include:
Utilizing high-reactivity PFP esters for the solution-phase attachment of GalNAc clusters to amine-modified RNA. This method consistently yields higher-purity conjugates compared to standard on-column methods.
We utilize specialized trivalent GalNAc architectures that maximize the "cluster glycoside effect," significantly enhancing binding affinity to ASGPR clusters on the cell surface.
Selection of biocompatible, biodegradable, and rigid linkers that maintain the spatial orientation of the GalNAc sugars, preventing interference with the RNA's biological activity.
Advanced HPLC and ion-exchange chromatography systems calibrated specifically for the separation of conjugated RNA from unreacted ligands and truncated sequences.
We begin by synthesizing your custom RNA or ASO sequence with a site-specific terminal amine modification (typically 5' or 3'). The crude material is purified via HPLC to ensure a high-quality starting substrate.
The GalNAc ligand is activated as a reactive PFP ester. Simultaneously, the amine-modified RNA is buffer-exchanged into a solution-phase reaction environment optimized for pH and salt concentration.
The activated GalNAc cluster reacts with the RNA in an aqueous or semi-aqueous solution. This environment allows for better mass transfer and higher coupling efficiency than solid-phase resins.
Post-reaction, the mixture undergoes rigorous purification (HPLC or PAGE) to isolate the GalNAc-RNA conjugate. Residual ligands and unreacted RNA are removed, followed by desalting into the desired final buffer.
Every batch is analyzed using LC-MS to confirm mass identity and purity (>95%). We also perform gel electrophoresis to verify structural integrity and the absence of degradation.
Journal: Molecules
DOI: 10.3390/molecules22081356
Published: 2017
IF: 4.6
Results: This research article presents a comparative evaluation of two distinct strategies for synthesizing 5'-GalNAc-conjugated ASOs: a solution-phase method and a solid-phase method. The authors, from Ionis Pharmaceuticals, systematically compared these approaches at a 1.1 mmol scale using a standard MOE gapmer ASO. The solution-phase strategy involved synthesizing and purifying a 5'-aminohexyl-modified ASO first, followed by conjugation in solution with a GalNAc ligand activated as a pentafluorophenyl ester. In contrast, the solid-phase approach utilized a custom GalNAc phosphoramidite that was coupled directly to the support-bound oligonucleotide during automated synthesis. The study meticulously optimized the solid-phase coupling conditions, investigating factors like reagent equivalents, temperature, and reaction time to achieve over 90% efficiency. A critical finding was the development of a specialized reversed-phase HPLC purification method capable of separating the conjugated product from unconjugated ASO, which was essential for the solid-phase route. The comprehensive comparison revealed that the solution-phase method yielded material with slightly higher overall purity (97.7%) and yield (58%), while the solid-phase method offered a significant operational advantage by being faster and requiring fewer unit operations, despite a slightly lower yield of 47%. The analysis also identified distinct impurity profiles inherent to each method, providing valuable insights for process selection based on the specific requirements of purity, yield, and scalability for producing these targeted therapeutic oligonucleotides.
Metabolic Disease Research
GalNAc-RNA conjugates are primarily used to target genes in the liver responsible for metabolic disorders such as hypercholesterolemia and type 2 diabetes, providing a pathway for silencing key regulators of lipid metabolism.
Viral Hepatitis Therapeutics
Our service supports the development of siRNA and ASOs designed to inhibit the replication of Hepatitis B (HBV) and Hepatitis C (HCV) viruses by targeting viral transcripts directly within the hepatocyte.
Coagulation Factor Modulation
Our technology is used to develop agents that regulate the production of clotting factors, which are essential for investigating new treatments for hemophilia and various thrombotic disorders.
Enzyme Replacement Research
Our conjugates can be used to deliver RNA that modulates enzyme expression or provides the foundation for transient enzyme expression strategies in the liver, aiding in the study of metabolic enzyme deficiencies.
Superior Purity Profiles
By performing conjugation in the solution phase, we achieve a level of purity that exceeds solid-phase alternatives. This reduces the presence of truncated "failed sequences" that can interfere with biological assays and increase toxicity profiles in animal models.
Enhanced Yield for Complex Payloads
Solution-phase chemistry allows for precise control over stoichiometry and reaction kinetics. This is particularly beneficial for high-value RNA sequences where every milligram counts, ensuring maximum conversion of your starting material into the final conjugate.
Site-Specific Conjugation Accuracy
Our technology ensures that the GalNAc ligand is attached precisely at the intended amine-modified site. This preserves the structural integrity of the RNA and avoids the random labeling issues that can occur with less sophisticated delivery methods.
Scalable Manufacturing Processes
Unlike solid-phase synthesis, which can be limited by resin capacity and pressure issues, our solution-phase process is highly scalable. We can easily transition your project from initial discovery scales to larger preclinical requirements without changing the conjugation chemistry.
The purity of the GalNAc-siRNA conjugates provided by CD BioGlyco was exceptional. We observed a significant increase in gene silencing potency in our murine liver models compared to previous batches from other vendors. Their solution-phase approach clearly makes a difference in product quality.
— Dr. J.L., Principal Scientist, Drug Discovery Department
Working with CD BioGlyco has streamlined our preclinical workflow. Their technical team provided invaluable advice on linker selection, and the LC-MS data provided with our order gave us full confidence in the material we were injecting.
— Manager, RNA Therapeutics Group, Biotechnology Division
We required a high-scale production of a GalNAc-ASO for a safety study. CD BioGlyco delivered the gram-scale material ahead of schedule and with a purity profile that exceeded our internal standards. Highly recommended for targeted delivery needs.
— Dr. R.S., Head of Molecular Biology, Research & Development
The liver specificity we achieved with CD BioGlyco's triantennary GalNAc clusters was remarkable. We saw virtually no off-target effects in the kidney or spleen, allowing us to accurately characterize the function of our target hepatic enzyme.
— Senior Researcher, Metabolic Diseases Unit
To complement our solution phase-based GalNAc-RNA delivery service, we offer a suite of high-end purification and synthesis options:
Ideal for removing small molecule impurities and preparing RNA for downstream biological assays.
A rapid and cost-effective method for purifying synthetic RNA fragments with high efficiency.
Our gold-standard purification for achieving maximum purity and removing sequence isomers.
Best suited for high-resolution separation of long RNA sequences or structurally complex oligonucleotides.
CD BioGlyco is dedicated to advancing the field of targeted RNA therapeutics through precision chemistry and expert service. Our solution phase-based GalNAc-RNA delivery service provides the purity, scale, and reliability needed to move your hepatocyte-targeting projects from the lab to the clinic. Whether you are working on a novel metabolic target or optimizing a viral hepatitis lead, our team is ready to support your success. For technical inquiries, project quotes, or to discuss your specific RNA delivery requirements, please contact us!
Reference
